Journal article
High-specific-activity (131)iodine-metaiodobenzylguanidine for therapy of unresectable pheochromocytoma and paraganglioma
Future oncology (London, England), Vol.17(10), pp.1131-1141
04/01/2021
DOI: 10.2217/fon-2020-0625
PMCID: PMC7927907
PMID: 33506713
Abstract
Pheochromocytomas and paragangliomas (PPG) are rare cancers arising from the adrenal medulla (pheochromocytoma) or autonomic ganglia (paraganglioma). They have highly variable biological behavior. Most PPG express high affinity norepinephrine transporters, allowing active uptake of the norepinephrine analog, (131)iodine-metaiodobenzylguanidine (I-131-MIBG). Low-specific-activity forms of I-131-MIBG have been used since 1983 for therapy of PPG. High-specific-activity-I-131-MIBG therapy improves hypertension management, induces partial radiological response or stable disease, decreases biochemical markers of disease activity and is well tolerated by patients. This drug, approved in the USA in July 2018, is the first approved agent for patients with unresectable, locally advanced or metastatic PPG and imaging evidence of metaiodobenzylguanidine uptake, who require systemic anticancer therapy.
Details
- Title: Subtitle
- High-specific-activity (131)iodine-metaiodobenzylguanidine for therapy of unresectable pheochromocytoma and paraganglioma
- Creators
- Joseph S. Dillon - University of IowaDavid Bushnell - University of IowaDouglas E. Laux - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Future oncology (London, England), Vol.17(10), pp.1131-1141
- Publisher
- Future Medicine Ltd
- DOI
- 10.2217/fon-2020-0625
- PMID
- 33506713
- PMCID
- PMC7927907
- ISSN
- 1479-6694
- eISSN
- 1744-8301
- Number of pages
- 11
- Grant note
- Progenics, Inc.
- Language
- English
- Date published
- 04/01/2021
- Academic Unit
- Radiology; Hematology, Oncology, and Blood & Marrow Transplantation; Fraternal Order of Eagles Diabetes Research Center; Endocrinology and Metabolism; Internal Medicine
- Record Identifier
- 9984318721502771
Metrics
12 Record Views